Acebutolol hydrochloride

(ays-BYOU-toe-lohl] Pregnancy Category: B

Apo-Acebutolol M, Monitan M, Novo-Acebutolol M, Nu-Acebutolol M, Rhotral M, Sectral [Rx] Classification: Beta-adrenergic blocking agent

See also Beta-Adrenergic Blocking Agents.

Action/Kinetics: Predominantly beta-1 blocking activity but will inhibit beta-2 receptors at higher doses. Some intrinsic sympathomimetic activity. ty2: 3—4 hr. Low lipid solubility. Onset: 1-1/2 hr; Peak: 2-4 hr; Halflife: 3-4 hr; Duration: 24-30 hr. Metabolized in liver and excreted in urine and bile. Fifteen to 20% excreted unchanged.

Uses: Hypertension (either alone or with other antihypertensive agents such as thiazide diuretics). Premature ventricular contractions. Contraindications: Hypersensitivity to acebutolol, cardiogenic shock, 2nd or 3rd degree heart block, sinus bradycardia, congestive heart failure, cardiac failure. Additional Contraindications: Severe, persistent bradycardia. Special Concerns: Aortic or mitral valve disease, asthma, COPD, diabetes mellitus, major surgery, renal disease, thyroid disease, well-compensated heart failure. Side Effects: Oral: Dry mouth. CV: Bradycardia, CHF, cold extremities, postural hypotension, profound hypotension, 2nd or 3rd degree heart block. CNS: Catatonia, depression, dizziness, drowsiness, fatigue, hallucinations, insomnia, lethargy, mental changes, memory loss, strange dreams. GI: Diarrhea, ischemic colitis, nausea, mesenteric arterial thrombosis, vomiting. Hematologic: Agranulocytosis, thrombocytopenia. Allergic: Fever, sore throat, respiratory distress, rash, pharyngitis, laryngospasm, anaphylaxis. Skin: Pruritus, rash, increased skin pigmentation, sweating, dry skin, alopecia, skin irritation, psoriasis. Ophthalmic: Dry, burning eyes. GU: Dysuria, impotence, nocturia. Other: Hypoglycemia or hyperglycemia. Respiratory: Bronchospasm, dyspnea, wheezing. Drug Interactions: See also Drug Interactions for Beta-Adrenergic Blocking Agents and Antihypertensive Agents.

How Supplied: Capsule: 200 mg, 400 mg

Dosage-

0 0

Post a comment